AR029611A1 - Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4 - Google Patents
Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4Info
- Publication number
- AR029611A1 AR029611A1 ARP000100290A ARP000100290A AR029611A1 AR 029611 A1 AR029611 A1 AR 029611A1 AR P000100290 A ARP000100290 A AR P000100290A AR P000100290 A ARP000100290 A AR P000100290A AR 029611 A1 AR029611 A1 AR 029611A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- vla
- inhibit
- leucocits
- adhesion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
Se describen compuestos que se adhieren a VLA-4. Algunos de estos compuestos inhiben también la adhesion de leucocitos y, en particular, la adhesion de leucocitos intermediada por VLA-4. Dichos compuestos son utiles para el tratamiento de enfermedades inflamatorias en un paciente mamífero, por ejemplo, en un ser humano, tal como asma, enfermedad de Alzheimer, aterosclerosis, demencia causada por SIDA, diabetes, enfermedades intestinales inflamatorias, artritis reumatoide, trasplantes de tejidos, metástasis de tumores e isquemia de miocardio. Los compuestos pueden administrarse también para el tratamiento de enfermedades cerebrales inflamatorias tales como esclerosis multiple.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23747399A | 1999-01-25 | 1999-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR029611A1 true AR029611A1 (es) | 2003-07-10 |
Family
ID=22893870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000100290A AR029611A1 (es) | 1999-01-25 | 2000-01-24 | Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1150997A1 (es) |
JP (1) | JP2002539080A (es) |
CN (1) | CN1185250C (es) |
AR (1) | AR029611A1 (es) |
AU (1) | AU3348700A (es) |
CA (1) | CA2359114A1 (es) |
HK (1) | HK1044549B (es) |
MX (1) | MXPA01007394A (es) |
WO (1) | WO2000043415A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
JP2005022976A (ja) * | 2001-07-18 | 2005-01-27 | Ajinomoto Co Inc | カルボン酸誘導体 |
US6916813B2 (en) | 2001-12-10 | 2005-07-12 | Bristol-Myers Squibb Co. | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
CA2514125A1 (en) * | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
MXPA05010883A (es) | 2003-04-10 | 2006-01-23 | Amgen Inc | Derivados de amina ciclica y su uso en el tratamiento de trastornos inflamatorios relacionados mediados por bradiquinina. |
WO2018053446A1 (en) * | 2016-09-18 | 2018-03-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Yap1 inhibitors that target the interaction of yap1 with oct4 |
PE20211450A1 (es) | 2018-03-14 | 2021-08-05 | H Lee Moffitt Cancer Ct & Res | Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1102316A (en) * | 1975-12-09 | 1981-06-02 | Shosuke Okamoto | N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof |
FR2679903B1 (fr) * | 1991-08-02 | 1993-12-03 | Elf Sanofi | Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant. |
AU1354292A (en) * | 1991-03-18 | 1992-10-21 | Pentapharm Ag | Parasubstituted phenylalanine derivates |
WO1996001644A1 (en) * | 1994-07-11 | 1996-01-25 | Athena Neurosciences, Inc. | Inhibitors of leukocyte adhesion |
US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
DE69833654T2 (de) * | 1997-05-29 | 2006-12-14 | Merck & Co., Inc. (A New Jersey Corp.) | Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren |
JP2002512625A (ja) * | 1997-05-29 | 2002-04-23 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としての複素環アミド化合物 |
CN1133648C (zh) * | 1997-07-31 | 2004-01-07 | 伊兰药品公司 | 抑制vla-4介导的白细胞粘附的取代的苯丙氨酸型化合物 |
-
2000
- 2000-01-21 EP EP00911618A patent/EP1150997A1/en not_active Withdrawn
- 2000-01-21 JP JP2000594831A patent/JP2002539080A/ja active Pending
- 2000-01-21 WO PCT/US2000/001603 patent/WO2000043415A1/en not_active Application Discontinuation
- 2000-01-21 AU AU33487/00A patent/AU3348700A/en not_active Abandoned
- 2000-01-21 CN CNB008031037A patent/CN1185250C/zh not_active Expired - Fee Related
- 2000-01-21 MX MXPA01007394A patent/MXPA01007394A/es not_active IP Right Cessation
- 2000-01-21 CA CA002359114A patent/CA2359114A1/en not_active Abandoned
- 2000-01-24 AR ARP000100290A patent/AR029611A1/es unknown
-
2002
- 2002-08-23 HK HK02106216.3A patent/HK1044549B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1185250C (zh) | 2005-01-19 |
WO2000043415A1 (en) | 2000-07-27 |
CN1340058A (zh) | 2002-03-13 |
CA2359114A1 (en) | 2000-07-27 |
JP2002539080A (ja) | 2002-11-19 |
AU3348700A (en) | 2000-08-07 |
HK1044549B (zh) | 2005-05-27 |
HK1044549A1 (en) | 2002-10-25 |
MXPA01007394A (es) | 2002-04-09 |
EP1150997A1 (en) | 2001-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR013384A1 (es) | Compuestos del tipo de fenilalanina substituidos que inhiben la adhesion de leucocitos intermediada por vla-4 | |
ES2221183T3 (es) | Compuestos oxicarbamilo que inhiben la adhesion de leucocitos mediada por vla-4. | |
BR9812118A (pt) | Compostos do tipo 4-amino-fenilalanina que inibem adesão de leucócito mediada por vla-4 | |
BR9811569A (pt) | Compostos que inibem a adesão de leucócito mediada por vla-4 | |
BR9811599A (pt) | Compostos de dipetìdeo que inibem adesão de leucócito mediada por vla-4 | |
BR0007663A (pt) | Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4 | |
HK1072608A1 (en) | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | |
BR9811573A (pt) | Compostos de benzila que inibem a adesão de leucócitos mediada por vla-4 | |
BR9811594A (pt) | Compostos de dipeptìdeo sulfonilados que inibem adesão de leucócito mediada por vla-4 | |
BR9812111A (pt) | Dipeptìdeo e compostos correlatos que inibem adesão de leucócito mediada por vla-4 | |
BRPI0513143A (pt) | antagonistas de vla-4 multivalentes compreendendo porções poliméricas | |
EA200401561A1 (ru) | Гетероарильные соединения, которые ингибируют опосредованную 4-интегринами адгезию лейкоцитов | |
WO2000043354A3 (en) | Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 | |
ZA200803016B (en) | Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 | |
AU3246600A (en) | Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists | |
WO2002008201A3 (en) | Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4 | |
AR029611A1 (es) | Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4 | |
AR022405A1 (es) | Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos | |
AR026105A1 (es) | Compuetos heteroarilo, heterociclico y ilo que | |
AR042047A1 (es) | Compuestos de heteroarilo que inhiben la adhesion de leucocitos mediada por integrinas alfa 4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |